Fig. 4

Comparative quantitative high-throughput screening (qHTS) using compounds from the MIPE Oncology 4.0 library identifies compounds with preferential activity against c.del1380A CDH1 SB.mhdgc-1 cells compared to SB.msgc-1 gastric cancer cells. a Bubble diagram of drug phenotypes by compound class of SB.mhdgc-1 versus SB.msgc-1 cells depicting class activities (number of compounds per drug class) measured by area under the curve (AUC) (drug class activities ≥2 standard deviations from the mean of ΔAUC(% AUC(c.1380delA SB.mhdgc-1/SB.msgc-1) being considered significantly more active in the respective cell line). b Drug classes with activity in both c.del1380A CDH1 SB.mhdgc-1 and SB.msgc-1 gastric cancer cells by maximum response (MAXR) <30%. Enrichment (number of active compounds in a target class relative to total number of compounds for that target class versus enrichment for each target, compared to background; Fishers exact test, 2-tailed)